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S U M M A R Y
The ﬁrst occurrence of New Delhi metallo-b-lactamase 5 (NDM-5), carried on an IncI1-Ig-type plasmid
of >93 kb in a multidrug-resistant Escherichia coli strain in Kafr El-Sheikh, Egypt, is reported. The strain
was isolated from a wound pus swab from a patient diagnosed with a fracture of the right femur. This
E. coli strain was found to belong to sequence type (ST) 5018 and also to carry other resistance genes,
including blaCTX-M-15, blaCMY-42, blaOXA-1, and aac(60)-Ib-cr.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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New Delhi metallo-b-lactamase 1 (NDM-1) has received global
attention due ﬁrst to its high level of resistance to many different
b-lactams, except aztreonam, second to its dissemination world-
wide to different countries, third to its association with hospital-
acquired infections, and fourth to its acquisition by many common
Gram-negative bacteria.1 NDM-1 was ﬁrst discovered in Klebsiella
pneumoniae in a Swedish patient previously hospitalized in India.
The discovery of NDM-5 was similar; it was ﬁrst reported in
2011 in an Escherichia coli isolate recovered from a patient in the
UK after a recent hospitalization in India.2 It has since been
reported from many other countries, including India, Algeria,3
Spain, Japan, Australia, the USA, and China.4 NDM-5 differs from
NDM-1 by two amino acid substitutions (Val88Leu and
Met154Leu), which cause a reduced susceptibility of E. coli
TOP10 transformants to extended-spectrum cephalosporins and* Corresponding author. Tel.: +81 82 424 7897; fax: +81 82 424 7916.
E-mail address: tadashis@hiroshima-u.ac.jp (T. Shimamoto).
http://dx.doi.org/10.1016/j.ijid.2016.05.003
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).carbapenems.2 The ﬁrst NDM-5-producing carbapenem-resistant
E. coli isolate identiﬁed in Egypt is described herein.
2. Case report
A 65-year-old man was admitted to the emergency department
of a hospital in the city of Kafr El-Sheikh, Egypt, on May 30, 2014,
with a diagnosis of right femur fracture resulting in the formation
of a deep wound. After surgery on May 31, 2014, the patient was
transferred to the department of orthopedics for the completion of
treatment, and empiric intravenous ceftriaxone (1 g twice daily for
13 days) was given to prevent bacterial infection. Unfortunately,
the wound began to exude yellow pus on June 13, 2014, and the
patient was started on intravenous levoﬂoxacin (0.5 g twice daily
for 6 days). On June 16, 2014, a multidrug-resistant E. coli strain,
designated EC169, was isolated from the wound pus specimen. In
accordance with the drug resistance pattern of EC169, the patient’s
antibiotic treatment was changed to intramuscular amikacin (1 g
twice daily). The patient recovered after 9 days, and a wound pus
swab was negative for E. coli.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(bioMe´rieux, Marcy l’Etoile, France). The broth microdilution
method was used to determine the minimum inhibitory
concentrations (MICs) of selected antimicrobials; the results
were interpreted in accordance with the Clinical and Laboratory
Standards Institute (CLSI) guidelines. Amoxicillin, cefotaxime,
ceftazidime, and ceftriaxone powders were supplied by Sigma-
Aldrich (Tokyo, Japan), meropenem, gentamicin, nalidixic acid,
norﬂoxacin, and colistin by Wako Pure Chemical Ind. Ltd (Osaka,
Japan), imipenem, doripenem, and cefoperazone by LKT Labora-
tories, Inc. (Minnesota, USA), and tetracycline powder was
purchased from Nacalai Tesque (Kyoto, Japan). For all experi-
ments, the puriﬁed powder of each antibiotic was diluted
following the CLSI recommendations. The reference
strain Escherichia coli ATCC 25922 was included as a quality
control.
EC169 showed resistance to imipenem, meropenem, doripe-
nem, aztreonam, amoxicillin, cefotaxime, ceftazidime, cefoper-
azone, ceftriaxone, gentamicin, nalidixic acid, tetracycline, and
norﬂoxacin, while it was sensitive to amikacin and colistin
(Table 1). EC169 was also positive on the modiﬁed Hodge test,
by carbapenem inactivation method (CIM), and when tested with
the MBL method, using two disks containing 30 mg of ceftazidime
and one disk containing 3 mg of sodium mercaptoacetic acid (SMA)
(Eiken Chemical Co. Ltd, Tokyo, Japan), indicating the production of
metallo-b-lactamase. Of note, The CIM consists of two steps: (1)
incubation of a meropenem disk with the isolate tested, and (2)
incubation of this meropenem disk with the Escherichia coli ATCC
25922 strain. Carbapenemase activity can be detected easily after
the second incubation step by the absence of an inhibition zone,
which indicates enzymatic hydrolysis of meropenem during the
ﬁrst incubation step.
Following this, PCR and DNA sequencing were used to screen for
carbapenemase-encoding genes,5 extended-spectrum b-lacta-
mases (ESBLs), plasmid-mediated quinolone resistance genes,
integrons, and 16S rRNA methylases. PCR fragments were puriﬁed
using a FastGene Gel/PCR Extraction Kit (Nippon Genetics Co.,
Tokyo, Japan). Both DNA strands of the PCR product were
sequenced using a 3730xl DNA Analyzer (Applied Biosystems,
Foster City, CA, USA).
The results demonstrated that EC169 carried not only blaNDM-5,
but also blaCTX-M-15, blaCMY-42, blaOXA-1, aac(6
0)-Ib-cr, and a class
1 integron with two gene cassettes (dfrA17–aadA5). Multilocus
sequence typing (MLST) was performed using seven housekeeping
genes (adk, fumC, icd, purA, gyrB, recA, and mdh), according to the
Escherichia coli MLST Database (http://mlst.warwick.ac.uk/mlst/Table 1
Minimum inhibitory concentrations for the NDM-5-producing Escherichia coli
Antimicrobial Minimum inhibitory concentration (mg/ml)
IMP 32
MEM 32
DOR 32
AZM 512
AMX 512
CTX 512
CAZ 512
CFP 512
CRO 512
GEN 256
NAL 512
TET 256
NOR 128
CST 1
IMP, imipenem; MEM, meropenem; DOR, doripenem; AZM, aztreonam; AMX,
amoxicillin; CTX, cefotaxime; CAZ, ceftazidime; CFP, cefoperazone; CRO, ceftriax-
one; GEN, gentamicin, NAL, nalidixic acid; TET, tetracycline; NOR, norﬂoxacin; CST,
colistin.dbs/Ecoli). The results indicated that EC169 belongs to sequence
type (ST) 5018.
PCR mapping and DNA sequencing were used to analyze the
immediate genetic environment of the blaNDM-5 gene using
primers speciﬁc for the genetic environment of previously
published blaNDM genes. The insertion sequence ISAba125 was
identiﬁed upstream from the blaNDM-5 gene, and the bleomycin
resistance gene bleMBL was identiﬁed downstream from the
blaNDM-5 gene. Southern blot hybridization showed that blaNDM-5
was located on a plasmid of >93 kb. Probe labeling and membrane
hybridization were performed according to the protocol of the
Amersham ECL Direct Nucleic Acid Labeling and Detection System
(GE Healthcare Japan, Tokyo, Japan). Transferability of the blaNDM-5-
carrying plasmid was performed by conjugation experiment
between the clinical donor isolate (EC169) and azide-resistant
E. coli strain J53 as a recipient. The transconjugants were
selected on MacConkey agar plates containing 4 mg/ml meropenem
and 150 mg/ml sodium azide. Unfortunately, conjugation and
mating experiments were unsuccessful after several attempts,
indicating that this plasmid is unconjugable.
PCR-based replicon typing (inc/rep PCR) was applied to
determine the Inc type of the NDM-5-carrying plasmid. This
plasmid was cut and puriﬁed from a low melting point agarose gel
using standard agarase treatment (Nippon Gene Co., Ltd, Toyama,
Japan) and used as a DNA template for inc/rep PCR. The result
revealed that the NDM-5-carrying plasmid belonged to the IncI1-
Ig type.
3. Discussion
To date, 16 variants of NDM-type b-lactamases (NDM-1 to
NDM-16) have been detected and assigned according to the gene
bank available at the Lahey Clinic website (see http://www.lahey.
org/studies/other.asp#table1). However, only NDM-11 and
NDM-25 have been reported previously in Egypt. The discovery
of blaNDM-5 in a clinical E. coli isolate from a patient with no history
of travel beyond the Egyptian border probably suggests that blaNDM-5
is an autochthonous genetic determinant in Egypt. The overuse
and/or misuse of antimicrobials in Egyptian hospitals and the
community may be responsible for the development of high levels of
antimicrobial resistance. Due to the poor hygiene conditions in
developing countries like Egypt, the food chain and water may
comprise one of the possible sources that help the spread of these
resistance genes. Moreover, NDM-5 was recently reported in
Escherichia coli ST1284 from a rectal swab of a domestic dog
in Algeria. Also, cases of NDM-5 have arisen in the community in
China without hospitalization (E. coli ST5131) or a travel history
(Klebsiella pneumoniae ST14).
The MLST analysis revealed that E. coli EC169 belongs to
ST5018, which is completely unlike the ST types of NDM-5-
producing E. coli detected in the UK (ST648),2 India (ST648), Algeria
(ST2659),3 Spain (ST448), Japan (ST540), Australia (ST648), the USA
(ST167), and China (ST167).4 This appears to be the ﬁrst report of
an ST5018 E. coli strain expressing NDM-5 b-lactamase. The
genetic environment of blaNDM-5 is very similar to that previously
described for most NDM-1-producing Enterobacteriaceae.2,4 Other
genetic determinants, such as blaCTX-M-15
2,4 and class 1 integron
(dfrA17–aadA5),2 have also been reported in NDM-5-producers.
In conclusion, the worldwide dissemination of NDM-producing
Gram-negative bacteria is of great concern. Medical authorities
must implement antimicrobial programs and infection control
policies to effectively prevent the rapid spread of these genetic
determinants. The increasing bacterial drug resistance is a forceful
reminder that our world is very close to the situation in the pre-
antibiotic era, especially because there are no new antibiotics in
the pipeline.
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